Icon One

Trial Data. Revealed.

ELIAS Animal Health has begun to evaluate the power of its ELIAS cancer immunotherapy (ECI ®), a proprietary personalized treatment platform that combines a personalized cancer vaccination followed by ex vivo activated “killer” T cell therapy. This dual approach is what makes the ELIAS approach distinct from other cancer immunotherapies. The objective of the clinical trials is to determine whether ECI used in combination with surgery produces better outcomes than treatment with surgery and chemotherapy alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The promise of improved disease survival outcomes and better quality of life for cancer patients is being revealed in the data.

ACVIM Video/Presentation

Autologous Activated T cell Therapy
for Canine Osteosarcoma
Brian K Flesner, DVM, MS, DACVIM (Oncology), University of Missouri
Presented at ACVIM 2018, Seattle, WA

Intro, Diagnosis, Staging and Protocol

Adverse Events

Efficacy, Outcomes & Case Studies

Key Insights, Acknowledgments
and Summary

Current ELIAS Animal Health Canine Clinical Trials. Enrollment Completed.

Trial Type Cancer Indication
Combination of chemotherapy and ECI ® therapy to treat newly diagnosed B-cell Lymphoma in dogs Newly-diagnosed B cell lymphoma
Combination of surgery and ECI ® therapy to treat newly diagnosed osteosarcoma in dogs Newly-diagnosed appendicular osteosarcoma
Both trial types Osteosarcoma, B cell lymphoma, other cancers
Icon Two

Real Cancer Patients. Helped.

While the data is promising, the effect on the lives of beloved dogs is truly inspiring. Families have also gained more time with their cherished companions who are enjoying a better quality of life. This is why we're working so hard to advance cancer therapy in dogs.


See Roscoe in Action

Safety Studies. Completed.

Adverse events reported were mostly mild to moderate and were typically transient. For a complete list of the most common side effects, click on the below link

Most Common Side Effects